• Mashup Score: 0
    HOME - 2 year(s) ago

    Skip to content Search…

    Tweet Tweets with this article
    • 👉NEW PUBLICATION ALERT from Gus Cho lab! https://t.co/RiTJLHPnjS https://t.co/TvNzkZ35ws @CircRes @WUDeptMedicine

  • Mashup Score: 0

    Oh and colleagues demonstrate that the DUSP6–RSK1 axis is involved in the transformation of myeloproliferative neoplasms to secondary acute myeloid leukemia and that DUSP6 mediates the response to JAK2 inhibition.

    Tweet Tweets with this article
    • Check out this paper in @NatureCancer on research coming out of @mpndoc lab about a possible new target, DUSP6, for myeloid malignancies. Congrats to all who contributed to this exciting research! @TimKong_ @HuangLabMcGill @HmzaCelik @challenlab @yangck_ https://t.co/1dUy4Wd4O1

  • Mashup Score: 0

    Oral and Poster Abstracts Oral 634. Myeloproliferative Syndromes: Clinical and Epidemiological: Towards Personalized Medicine in Myeloproliferative Neoplasms and Mastocytosis: New and Repurposed Drugs for Unmet Clinical Needs Biological therapies, MPN, Chronic Myeloid Malignancies, drug development, hematopoiesis, Diseases, Therapies, Myeloid Malignancies, Biological…

    Tweet Tweets with this article
    • Dr. Stephen Oh @mpndoc, Co-Chief and Associate Professor @WashUHeme will be giving an oral presentation on Pacritinib (ACVR1 inhibitor) & Significant Anemia Benefit in Myelofibrosis Pts. Sun 12/11 5:15pm, 217-219 Conv Center. https://t.co/9UExurjGfi https://t.co/D5Ec0vcUjv